Manuelle Debunne

Manuelle Debunne has a diverse work experience in the pharmaceutical and biotechnology industries. Manuelle is currently the Chief Operating Officer at Nodus Oncology, a position they have held since September 2022. Before that, they served as the Director of Preclinical Programmes at Modulus Oncology Ltd. since August 2020.

Prior to their role at Modulus Oncology, they worked as the Director of Scientific Affairs at Cumulus Oncology, a start-up focused on developing anti-cancer therapies, starting from January 2019. Manuelle was responsible for building and managing the preclinical development strategy of various assets under license.

Manuelle also has experience in academia, having worked as an Entrepreneurial Lead in the iCURE program at Oxford Brookes University from June 2019 to September 2019. In this role, they explored the potential of a new technology related to drug development.

Earlier in their career, they served as the Company Creation Executive at The University of Edinburgh, where they evaluated the commercial potential of research projects in the medical field from July 2017 to December 2018.

Manuelle has also held positions at MedAnnex Limited, aTen Therapeutics Limited, and OncoBioPharm Limited. Manuelle worked as the Operations Director from January 2016 to July 2017, responsible for creating and managing core development plans for R&D activities. Prior to that, they were the Scientific Affairs Manager from April 2014 to December 2015, involved in planning and executing the development of compounds for both MedAnnex and OncoBioPharm.

Additionally, they have worked as a Consultant in sales and marketing at Actual Analytics, where they opened distribution channels for ActualTrack across Europe. Manuelle also had a brief consultancy role at MedAnnex Limited, assessing the characteristics of Annexuzlimab and designing the clinical development and regulatory strategy.

Manuelle's diverse experience also includes participating in the Saltire Fellowship program from September 2013 to April 2014, which provided their with leadership skills and international business experience.

Overall, Manuelle Debunne has a strong background in pharmaceutical and biotech industries, with expertise in preclinical development, scientific affairs, operations, and commercialization strategies.

Manuelle Debunne's education history is as follows:

Manuelle began their educational journey in 2003 at the University of Lille 1 Sciences and Technology, where they pursued a Master of Science degree in Genomic, Proteomic. Manuelle completed their degree in 2006.

In 2006, they enrolled at Université de Rouen to pursue a PhD in Pharmacology. Manuelle successfully completed their doctoral program in 2009.

In 2012, Manuelle obtained several certificates from Pharmaschool in Clinical Research, including Clinical Research Associate Certificates and Ultimate CRA development.

In 2013, they attended Babson College for a Fast track executive MBA program, although the completion status is not provided. Additionally, they obtained a PRINCE2 Practitioner certification in Project Management from APMG International in the same year.

Overall, Manuelle Debunne's education journey includes a Master's degree in Genomic, Proteomic, a PhD in Pharmacology, and additional certificates in Clinical Research and Project Management.